AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3535002 — intervention group
Group type: COMPARATOR
Intervention: Placebo/metoprolol 10 mg i.v. in patients with normal UAE
Number of subjects: 16
Study 3535002 — intervention group
Group type: COMPARATOR
Intervention: Placebo/metoprolol 10 mg i.v. in patients with incipient nephropathy
Number of subjects: 16
Study 3535002 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg/24 h and hydroflumethiazid 25 mg/24 h during long-term treatment
Number of subjects: 16
Study 31479384 — intervention group
Group type: EXPERIMENTAL
Intervention: High Motor Competence (HMC > 83)
Number of subjects: 160
Study 31479384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Motor Competence (LMC < 83)
Number of subjects: 160
Study 31479384 — intervention group
Group type: EXPERIMENTAL
Intervention: Females with Low Motor Competence (LMC)
Number of subjects: 160
Study 31479384 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 160
Study 31029260 — intervention group
Group type: EXPERIMENTAL
Intervention: Map-assisted coding
Number of subjects: 0
Study 31029260 — intervention group
Group type: COMPARATOR
Intervention: Usual coding
Number of subjects: 0
Study 28219674 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate toothpaste
Number of subjects: 135
Study 28219674 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine/calcium carbonate toothpaste
Number of subjects: 135
Study 28219674 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride toothpaste
Number of subjects: 135
Study 25955642 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeGiene mask
Number of subjects: 41
Study 25955642 — intervention group
Group type: EXPERIMENTAL
Intervention: MGDRx Eye Bag
Number of subjects: 41
Study 25955642 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EyeGiene mask and MGDRx Eye Bag
Number of subjects: 41
Study 24074511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-open PLIF procedure
Number of subjects: 40
Study 24074511 — intervention group
Group type: COMPARATOR
Intervention: Conventional PLIF procedure
Number of subjects: 40
Study 21858097 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AQ
Number of subjects: 3014
Study 21858097 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 3014
Study 19442011 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-endoscopic interlaminar approach
Number of subjects: 161
Study 19442011 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgical technique
Number of subjects: 161
Study 16399110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM) administered intravenously at a dosage of 2.0 mg/kg/h starting 12 hours before surgery until postoperative day 2
Number of subjects: 60
Study 16399110 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 60
Study 15276504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin infusion (25 microg for 7 minutes)
Number of subjects: 41
Study 15276504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bradykinin infusion)
Number of subjects: 41
Study 11422001 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg tablet every 12 h for 8 days) + Almotriptan (12.5 mg tablet on day 8)
Number of subjects: 12
Study 11422001 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan (12.5 mg tablet on day 8)
Number of subjects: 12
Study 9266290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core formulation
Number of subjects: 52
Study 9266290 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tablet
Number of subjects: 52
Study 9266290 — intervention group
Group type: COMPARATOR
Intervention: Intravenous formulation
Number of subjects: 52
Study 7905660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg) plus ASA (500 mg)
Number of subjects: 10
Study 7905660 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ASA (500 mg)
Number of subjects: 10
Study 3641787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin plus ampicillin (4 g fosfomycin every 8 h and 1 g ampicillin every 6 h)
Number of subjects: 32
Study 3641787 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus ampicillin (80 mg gentamicin every 8 h and 1 g ampicillin every 6 h)
Number of subjects: 32
Study 3641787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin plus ampicillin
Number of subjects: 32
Study 3641787 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus ampicillin
Number of subjects: 32
Study 31880993 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg BW oyster meat preload
Number of subjects: 20
Study 31880993 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g/kg BW oyster meat preload
Number of subjects: 20
Study 31880993 — intervention group
Group type: COMPARATOR
Intervention: 0 g/kg BW (control)
Number of subjects: 20
Study 30409497 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Bearing (WB) Merchant view
Number of subjects: 0
Study 30409497 — intervention group
Group type: COMPARATOR
Intervention: Non-Weight Bearing (NWB) view
Number of subjects: 0
Study 26732282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH; 3450 m terrestrial altitude)
Number of subjects: 16
Study 26732282 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH; 3450 m simulated altitude)
Number of subjects: 16
Study 26732282 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 16
Study 24504222 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 120
Study 22425161 — intervention group
Group type: EXPERIMENTAL
Intervention: Reloading multiband ligator with SD-c conductor
Number of subjects: 460
Study 22425161 — intervention group
Group type: COMPARATOR
Intervention: Disposable ligator (control group)
Number of subjects: 460
Study 20670420 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-Reducing (ER) training
Number of subjects: 8
Study 20670420 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-Enhancing (EE) training
Number of subjects: 8
Study 20670420 — intervention group
Group type: COMPARATOR
Intervention: Both ER and EE training
Number of subjects: 8
Study 18312804 — intervention group
Group type: COMPARATOR
Intervention: Staff-directed intervention
Number of subjects: 8727
Study 18312804 — intervention group
Group type: EXPERIMENTAL
Intervention: Program Champion-directed intervention
Number of subjects: 8727
Study 18312804 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8727
Study 16230259 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg irbesartan
Number of subjects: 4100
Study 16230259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4100
Study 16230259 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 4100
Study 12032008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 26
Study 9512880 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in vaccine trial
Number of subjects: 429
Study 9512880 — intervention group
Group type: COMPARATOR
Intervention: Not enrolled in vaccine trial
Number of subjects: 429
Study 7879333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematuria home screening
Number of subjects: 1575
Study 7879333 — intervention group
Group type: COMPARATOR
Intervention: Control group (unscreened cases)
Number of subjects: 1575
Study 7879333 — intervention group
Group type: COMPARATOR
Intervention: Control group (men solicited but declined screening)
Number of subjects: 1575
Study 2374829 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (n = 39, 60-70% HRR)
Number of subjects: 72
Study 2374829 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (n = 33, 30-40% HRR)
Number of subjects: 72
Study 623136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone (with possible addition of alpha methyldopa or propranolol)
Number of subjects: 300
Study 623136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone
Number of subjects: 300
Study 623136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (hydrochlorothiazide + alpha methyldopa)
Number of subjects: 300
Study 623136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 300
Study 28155175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 392
Study 28155175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 25842725 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingrehuatan decoction (QRHT)
Number of subjects: 12
Study 25842725 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy males)
Number of subjects: 12
Study 23260101 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric tube feeding
Number of subjects: 51
Study 23260101 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluids
Number of subjects: 51
Study 20884007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5, 10, or 20 mg) for a mean period of 29 weeks
Number of subjects: 29
Study 19349630 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-combination pharmacotherapy (nicotine patch, nicotine oral inhaler, and bupropion ad libitum)
Number of subjects: 127
Study 19349630 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch alone for a standard 10-week course
Number of subjects: 127
Study 19349630 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-combination pharmacotherapy
Number of subjects: 127
Study 19349630 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch alone
Number of subjects: 127
Study 17116766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 873
Study 17116766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 873
Study 17116766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 873
Study 17116766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 30 mg
Number of subjects: 873
Study 17116766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg
Number of subjects: 873
Study 17116766 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 873
Study 14985222 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc alone (10 mg Zn; n = 81)
Number of subjects: 246
Study 14985222 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus vitamins and minerals (Zn+VM; n = 82)
Number of subjects: 246
Study 14985222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 83)
Number of subjects: 246
Study 11371689 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) 600 mg twice daily
Number of subjects: 105
Study 11371689 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ABC-matched)
Number of subjects: 105
Study 11371689 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 105
Study 9682356 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 47
Study 9682356 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 47
Study 7991312 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased response velocity
Number of subjects: 25
Study 7991312 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased range of movement
Number of subjects: 25
Study 2647807 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 40
Study 2647807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant imagery
Number of subjects: 40
Study 2647807 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic imagery
Number of subjects: 40
Study 2647807 — intervention group
Group type: COMPARATOR
Intervention: Pain discussion (attention control)
Number of subjects: 40
Study 768962 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 35
Study 31744119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC) intake group (n = 10)
Number of subjects: 18
Study 31744119 — intervention group
Group type: COMPARATOR
Intervention: Cacao-free white chocolate (WC) intake group (n = 8)
Number of subjects: 18
Study 30269035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry diet (animal-based diet plus 30 g/day freeze-dried whole cranberry powder)
Number of subjects: 11
Study 30269035 — intervention group
Group type: COMPARATOR
Intervention: Control diet (animal-based diet plus 30 g/day placebo powder)
Number of subjects: 11
Study 26434651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive full-mouth intensive removal of subgingival dental plaque biofilms with scaling and root planning (group 2)
Number of subjects: 109
Study 26434651 — intervention group
Group type: COMPARATOR
Intervention: Standard cycle of supragingival mechanical scaling and polishing (group 1)
Number of subjects: 109
Study 25082595 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 μg/kg)
Number of subjects: 165
Study 25082595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 21572334 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 42
Study 21572334 — intervention group
Group type: COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 42
Study 20362507 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 3 weeks for 1 year)
Number of subjects: 120
Study 20362507 — intervention group
Group type: COMPARATOR
Intervention: No zoledronic acid (control group)
Number of subjects: 120
Study 20362507 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 120
Study 17327378 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARgamma agonist (rosiglitazone)
Number of subjects: 33
Study 17327378 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARalpha agonist (fenofibrate)
Number of subjects: 33
Study 17327378 — intervention group
Group type: COMPARATOR
Intervention: Combination of metyrapone and RU38486 (glucocorticoid blockade)
Number of subjects: 33
Study 15642026 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery and modification of surface topography (test group)
Number of subjects: 17
Study 15642026 — intervention group
Group type: COMPARATOR
Intervention: Resective surgery only (control group)
Number of subjects: 17
Study 12395217 — intervention group
Group type: EXPERIMENTAL
Intervention: Water dispersible beta-carotene powder (7.2 mg/d)
Number of subjects: 8
Study 12395217 — intervention group
Group type: EXPERIMENTAL
Intervention: Water dispersible beta-carotene powder (21.6 mg/d)
Number of subjects: 8
Study 12395217 — intervention group
Group type: COMPARATOR
Intervention: Carrot juice-based drink (6 mg/d)
Number of subjects: 8
Study 12395217 — intervention group
Group type: COMPARATOR
Intervention: Carrot juice-based drink (18 mg/d)
Number of subjects: 8
Study 10219465 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose benfotiamine (4 x 2 capsules/day, = 320 mg benfotiamine/day)
Number of subjects: 36
Study 10219465 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose benfotiamine (3 x 1 capsules/day)
Number of subjects: 36
Study 10219465 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with benfotiamine (3 x 1 tablets/day, = 150 mg benfotiamine/day)
Number of subjects: 36
Study 7727315 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), 700 mg/m2
Number of subjects: 332
Study 7727315 — intervention group
Group type: COMPARATOR
Intervention: No systemic therapy
Number of subjects: 332
Study 1895746 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon oil tamponade
Number of subjects: 30
Study 1895746 — intervention group
Group type: EXPERIMENTAL
Intervention: SF6-gas tamponade
Number of subjects: 30
Study 1895746 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS or air tamponade
Number of subjects: 30
Study 7273700 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (100 mg)
Number of subjects: 12
Study 7273700 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (100 mg)
Number of subjects: 12
Study 7273700 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg)
Number of subjects: 12
Study 7273700 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg)
Number of subjects: 12
Study 7273700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (100 mg)
Number of subjects: 12
Study 7273700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6303673 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg in the morning and placebo in the evening (Group I)
Number of subjects: 31
Study 6303673 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg twice daily (Group II)
Number of subjects: 31
Study 6303673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 31
Study 30507711 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose hormone therapy
Number of subjects: 342
Study 30507711 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy
Number of subjects: 342
Study 30507711 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 342
Study 30507711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 342
Study 30507711 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose hormone therapy (in women with a history of venous thrombosis)
Number of subjects: 342
Study 30507711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in women with a history of venous thrombosis)
Number of subjects: 342
Study 29358120 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intervention based on profound stress attunement
Number of subjects: 733
Study 27806355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering dialysate calcium concentration to 1.25 mmol/l
Number of subjects: 2
Study 27806355 — intervention group
Group type: COMPARATOR
Intervention: Control group with dialysate calcium concentration at 1.5 mmol/l
Number of subjects: 2
Study 25372006 — intervention group
Group type: EXPERIMENTAL
Intervention: home-based modified constraint-induced movement therapy (mCIMT)
Number of subjects: 22
Study 22506894 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression
Number of subjects: 0
Study 22506894 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 22506894 — intervention group
Group type: COMPARATOR
Intervention: Foot-tapping condition
Number of subjects: 0
Study 21060040 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin E on alternate days
Number of subjects: 11545
Study 21060040 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of vitamin C daily
Number of subjects: 11545
Study 21060040 — intervention group
Group type: COMPARATOR
Intervention: Placebo for vitamin E
Number of subjects: 11545
Study 21060040 — intervention group
Group type: COMPARATOR
Intervention: Placebo for vitamin C
Number of subjects: 11545
Study 17580445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 17580445 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15510184 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine SL (3 mg, four tablets)
Number of subjects: 130
Study 15510184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 12206276 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of pertinent information in immediate decision contexts
Number of subjects: 0
Study 12206276 — intervention group
Group type: COMPARATOR
Intervention: Absence of pertinent information
Number of subjects: 0
Study 11830911 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ionic toothbrush with an active battery
Number of subjects: 52
Study 11830911 — intervention group
Group type: COMPARATOR
Intervention: Inactive ionic toothbrush with an inactive battery
Number of subjects: 52
Study 8519720 — intervention group
Group type: EXPERIMENTAL
Intervention: INB+ (Intercostal nerve block with bupivacaine)
Number of subjects: 20
Study 8519720 — intervention group
Group type: COMPARATOR
Intervention: INB- (Intercostal nerve block with saline)
Number of subjects: 20
Study 1960255 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-fluoride dentifrice (1100 ppm F, NaF)
Number of subjects: 15
Study 1960255 — intervention group
Group type: COMPARATOR
Intervention: Positive control (1100-ppm F, NaF)
Number of subjects: 15
Study 1960255 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 15
Study 6763833 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 48
Study 6763833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 48
Study 6763833 — intervention group
Group type: COMPARATOR
Intervention: Self recordings of BP
Number of subjects: 48
Study 30248365 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (TAU) supplementation, single dose, dosage not specified
Number of subjects: 0
Study 27552212 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive garment
Number of subjects: 27
Study 27552212 — intervention group
Group type: COMPARATOR
Intervention: Regular sports shorts
Number of subjects: 27
Study 25943374 — intervention group
Group type: EXPERIMENTAL
Intervention: jack-knife position
Number of subjects: 104
Study 25943374 — intervention group
Group type: COMPARATOR
Intervention: lithotomy position
Number of subjects: 104
Study 23575698 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up exercises on a laparoscopic trainer immediately before surgery
Number of subjects: 237
Study 23575698 — intervention group
Group type: COMPARATOR
Intervention: No warm-up exercises (Control)
Number of subjects: 237
Study 21293156 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi and/or ARB therapy; 94% of patients had prior therapy with ACEi and/or ARB at the time of screening.
Number of subjects: 2303
Study 21293156 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned; control group not explicitly defined.
Number of subjects: 2303
Study 19222588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 2068
Study 19222588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2068